Spero Therapeutics(SPRO) Stock Price Today

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Spero Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update on Thursday, March 27, 2025
GlobeNewswireMar 18 08:00 ET
Spero Therapeutics to Present at TD Cowen 45th Annual Health Care Conference
GlobeNewswireFeb 25 07:00 ET
Insider Sale: CEO & President of $SPRO Sells 106,408 Shares
Quiver QuantitativeFeb 5 20:45 ET
The Analyst Verdict: Spero Therapeutics In The Eyes Of 4 Experts
BenzingaJan 30 16:00 ET
H.C. Wainwright Maintains Spero Therapeutics(SPRO.US) With Buy Rating, Maintains Target Price $5
Moomoo NewsJan 30 07:31 ET · Ratings
Express News | HC Wainwright & Co. Reiterates Buy on Spero Therapeutics, Maintains $5 Price Target
BenzingaJan 30 06:51 ET

Comments

Jaguar8

Oct 30, 2024 04:06

NEWS

$Spero Therapeutics (SPRO.US)$
Spero Therapeutics Announces SPR720 Phase 2a Interim Results and Provides a Business Update
Spero Therapeutics announced that its Phase 2a study of SPR720 for Nontuberculous Mycobacterial Pulmonary Disease failed to meet its primary endpoint. The interim analysis showed antimicrobial activity but insufficient separation from placebo, with safety concerns including three cases of reversible grade 3 hepatotoxicity. The company is suspending the SPR720 program and...

Jaguar8

Oct 17, 2024 04:06

NEWS

$Spero Therapeutics (SPRO.US)$
Spero Therapeutics Announces Presentation of SPR719 (Active Moiety of SPR720) In Vitro Data Demonstrating Low Propensity for the Development of Resistance at IDWeek 2024
Spero Therapeutics announced a poster presentation at IDWeek 2024 showcasing in vitro data on SPR719, the active moiety of SPR720, for treating nontuberculous mycobacterium pulmonary disease (NTM-PD). The study, conducted with Microbiologics, revealed:
1. SPR719's low propensity for resistance d...

Jaguar8

Oct 3, 2024 04:31

NEWS

$Spero Therapeutics (SPRO.US)$
Spero Therapeutics Announces Publication of SPR720 Phase 1 Lung Exposure Data in Antimicrobial Agents and Chemotherapy
Spero Therapeutics (Nasdaq: SPRO) has published data from its Phase 1 clinical trial assessing the intrapulmonary pharmacokinetics of SPR719, the active moiety of SPR720, in Antimicrobial Agents and Chemotherapy. The study, involving 33 healthy subjects, showed significant lung uptake and enhanced concentrations of SPR719 in epithelial lining fl...

Tonyco

Oct 1, 2024 02:39

$Metagenomi Technologies (MGX.US)$ $Lantronix (LTRX.US)$
$Fate Therapeutics (FATE.US)$
$Navitas Semiconductor (NVTS.US)$
Opened up some positions on these today.
Increased $Rivian Automotive (RIVN.US)$ , $X4 Pharmaceuticals (XFOR.US)$
Took profit on $FTC Solar (FTCI.US)$ , $GigaCloud Technology (GCT.US)$ and $Aurora Innovation (AUR.US)$
I'll be back in GCT and AUR for sure.
Still looking at $Spero Therapeutics (SPRO.US)$ and $Acacia Research (ACTG.US)$ too.
Exciting day for dips!

3

1

Tonyco

Sep 22, 2024 12:12

$Spero Therapeutics (SPRO.US)$
Gonna be looking for under 1.3 to hop on. However, 9 days until their P2 trial concludes. If momentum builds, it may push it really high before then plummet after. Or, as I am hoping, it sinks until the news drops and gets a temp boost.
Right now, it looks likely to drop due to the MACD death cross.. we shall see

SPRO Spero Therapeutics

Trade Overview

Capital Trend

News

Comments